<DOC>
	<DOCNO>NCT01333072</DOCNO>
	<brief_summary>The Biomarkers autism aripiprazole risperidone treatment ( BAART ) project provide evidence-based guidance selection monitor drug treatment autism . BAART involve 3 academic center across South Carolina . Although FDA approve use antipsychotic drug risperidone irritability associate autistic disorder , moderate response rate pivotal clinical trial concern tolerability weight gain force clinician select alternative drug treatment evidence-based support sparse .</brief_summary>
	<brief_title>Biomarkers Autism Aripiprazole Risperidone Treatment ( BAART )</brief_title>
	<detailed_description>The Biomarkers autism aripiprazole risperidone treatment ( BAART ) project provide evidence-based guidance selection monitor drug treatment autism . BAART involve 3 academic center across South Carolina expertise phenotyping patient autistic spectrum disorder , assess patient response clinical trial , expertise pharmacogenomic research . Although FDA approve use antipsychotic drug risperidone aripiprazole irritability associate autistic disorder , moderate response rate pivotal clinical trial concern tolerability weight gain force clinician select alternative drug treatment evidence-based support sparse . BAART assess predictor efficacy , tolerability , safety 200 child 6-17 year old autistic disorder ( AD ) double-blind , randomize 10 week treatment period either risperidone aripiprazole . Responders complete study may continue medication treatment three month . Factors consider include 1 ) psychiatric history ; 2 ) symptom response ; 3 ) psychosocial support ; 4 ) measure tolerability ; 5 ) serum prolactin brain-derived neurotrophic factor concentration ; 5 ) variety single nucleotide polymorphisms related target gene drug disposition transport , response , tolerability . The BAART project result evidence-based guideline selection monitor drug treatment child adolescent AD .</detailed_description>
	<mesh_term>Autistic Disorder</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<criteria>Inclusion Criteria Aged 6 17 year weight least 15 kg Meet DSMIV criterion AD , establish chart review , clinical judgment Autism Diagnostic Interview Revised ( ADIR ) criteria Clinical Global Impressions Severity ( CGIS ) score &gt; 4 ( moderately ill ) ABC Irritability subscale score &gt; 18 Mental age least 18 month If female sexually active , must agree acceptable method birth control trial Medication free adequate washout period ( 24 week prior enrollment ) psychoactive drug ( anticonvulsant permit seizure management dosage stable 4 week ) Parent/guardian able read provide inform consent . Exclusion Criteria Psychiatric disorder effectively manage psychoactive medication ( e.g . ADHD , MDD ) Prior diagnosis evidence genetic disorder may interfere assessment ( e.g . Fragile X syndrome , Fetal alcohol syndrome , history low birth weight ) assess personal family history , dysmorphology , clinical judgment . Prior use risperidone aripiprazole 2 week Seizure past 6 month History evidence medical condition would expose undue risk significant adverse event interfere assessment trial include limited hepatic , renal , respiratory , cardiovascular , endocrine , hematologic immunologic disease determine clinical judgment investigator Current suicidal homicidal risk Positive urine pregnancy test baseline Dependent substance , exception nicotine caffeine</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Autistic Disorder</keyword>
</DOC>